The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States

Ng, Daniel; Espinosa, Robert; Johnson, Scott J.; Walker, David; Gooch, Katherine

doi:10.1080/13696998.2017.1367300

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The core study sample included beneficiaries with OAB who were US residents, aged ≥ 65 years, and had continuous enrollment in Medicare Parts A, B, and D and no enrollment in Medicare Part C (Medicare Advantage). The presence of OAB was determined by one or more inpatient or outpatient facility claims or at least two Carrier file claims on separate dates with an OAB diagnosis code (Table 1 of the Electronic Supplementary Material [ESM]) [ 19 , 20 ]. Enrollment and medical claims data from 2005 were used to assess an individual’s earliest medical claim with an OAB diagnosis code for those who enrolled in Medicare prior to the start of Part D (1 January, 2006).…”

Section: Methodsmentioning

confidence: 99%

A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA

Campbell

Hines²,

Epstein³

et al. 2021

Drugs Aging

Self Cite

View full text Add to dashboard Cite

Background and Objective Antimuscarinics, drugs with anticholinergic properties, are frequently prescribed for overactive bladder, and anticholinergic burden is associated with adverse events. The “Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults” (Poly-ACH) measure was developed by the Pharmacy Quality Alliance and is used by the Centers for Medicare and Medicaid Services. Using the Poly-ACH measure, we assessed the prevalence of anticholinergic polypharmacy among Medicare patients in the USA with overactive bladder and determined associations between polypharmacy and medical conditions, care, and spending. Methods This was a retrospective cohort study of Medicare beneficiaries with overactive bladder (coverage period: 2006–2017). Anticholinergic polypharmacy, measured by the Poly-ACH, was defined as concurrent use of two or more anticholinergics, each with two or more prescription claims on different dates of service for ≥ 30 cumulative days. Change in annual frequency of anticholinergic polypharmacy was assessed using logistic regression. Associations between anticholinergic polypharmacy over 3 years and falls, fractures, mental status, and medical care spending were assessed with longitudinal regression models. Results In total, 226,712 patients contributed 940,201 person-years of follow-up after overactive bladder diagnosis. The share of patients meeting the Poly-ACH definition was 3.3% in 2006 and 1.7% in 2017. Women and nursing home residents had higher risks of anticholinergic polypharmacy. Having 1 year or more of positive Poly-ACH status in the 3 years prior was associated with higher rates of all outcomes. Conclusions Anticholinergic polypharmacy was uncommon among older adults with overactive bladder. Prevalence was higher among women and nursing home residents, and it was associated with negative outcomes, highlighting potential longitudinal implications of anticholinergic burden. Supplementary Information The online version contains supplementary material available at 10.1007/s40266-021-00901-2.

show abstract

Section: Methodsmentioning

confidence: 99%

A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA

Campbell

Hines²,

Epstein³

et al. 2021

Drugs Aging

Self Cite

View full text Add to dashboard Cite

show abstract

“…The OAB cohort was identified on the basis of the presence of medical encounters associated with one or more OAB-related International Classification of Diseases (ICD)-10 diagnostic codes (used within the Brazilian public health database) on inpatient or outpatient visits during the study period. As only 4-character ICD-10 codes were available in the Brazilian public health database (O Departamento de Informática do Sistema Único de Saúde, DATASUS), previously published lists of 5-digit ICD-9 codes for OAB [ 12 – 15 ] were mapped to corresponding 4-character ICD-10 codes (N32.8, Other specified disorders of the bladder; N39.4, Other specified urinary incontinence; R35.0, Frequency of micturition, R35.1 Nocturia, R39.1 Other difficulties with micturition, R39.8 Other symptoms and signs involving the genitourinary system) for identification of the cohort. All OAB codes were confirmed with clinical experts.…”

Section: Methodsmentioning

confidence: 99%

Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System

Lozano‐Ortega

Szabo

et al. 2020

Adv Ther

View full text Add to dashboard Cite

Introduction:In Brazil, current data on the use of healthcare resources to manage individuals with overactive bladder (OAB) are lacking. This study aimed to characterize contemporary treatment and the economic burden among patients with OAB managed under the Brazilian public health system (Sistema Ú nico de Saú de [SUS]). within the SUS. These data provide a snapshot of the management of patients with OAB in Brazil, with the patients seeking treatment under SUS likely representing a more burdened subpopulation. Key Summary PointsWhy carry out this study?An accurate understanding of the economic burden of overactive bladder (OAB) requires knowledge of both disease prevalence and contemporary management practices.While some studies of the prevalence of OAB in Brazil exist, studies exploring treatment practices and economic burden in relation to OAB are lacking.This study sought to characterize contemporary treatment and the economic burden associated with the management of patients with OAB in the Brazilian public health system. What was learned from the study?This study helped highlight the undertreatment of OAB within the Brazilian public health system, and helped quantify healthcare resource use and associated costs among those actively managed for OAB within that system.

show abstract

Cost-Effectiveness of Third-Line Therapies for Overactive Bladder

Cohen

2018

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States

Abstract: OAB patients who persisted on mirabegron treatment for at least 180 days had lower OAB-related healthcare costs and resource utilization compared with those who switched to onabotA.

Cited by 5 publications

References 17 publications

A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA

A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA

Management of Patients with Overactive Bladder in Brazil: A Retrospective Observational Study Using Data From the Brazilian Public Health System

Cost-Effectiveness of Third-Line Therapies for Overactive Bladder

Contact Info

Product

Resources

About